Bausch + Lomb Co. (NYSE:BLCO) Receives $20.00 Average PT from Analysts

Shares of Bausch + Lomb Co. (NYSE:BLCO) have earned a consensus recommendation of “Hold” from the twelve ratings firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $20.00.

A number of analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $23.00 target price on shares of Bausch + Lomb in a research report on Tuesday, February 18th. Needham & Company LLC reaffirmed a “hold” rating on shares of Bausch + Lomb in a research report on Thursday, February 20th. Morgan Stanley cut Bausch + Lomb from an “overweight” rating to an “equal weight” rating and set a $19.00 price objective for the company. in a research note on Monday, December 2nd. Citigroup lowered shares of Bausch + Lomb from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $24.00 to $22.00 in a research report on Wednesday, December 11th. Finally, Bank of America reduced their price target on shares of Bausch + Lomb from $18.00 to $17.00 and set an “underperform” rating for the company in a research report on Thursday, February 20th.

Bausch + Lomb Trading Up 0.2 %

NYSE BLCO opened at $15.94 on Friday. Bausch + Lomb has a 52 week low of $13.16 and a 52 week high of $21.69. The firm has a 50 day moving average of $16.38 and a two-hundred day moving average of $18.12. The stock has a market capitalization of $5.62 billion, a PE ratio of -17.52, a price-to-earnings-growth ratio of 0.85 and a beta of 0.49. The company has a quick ratio of 1.01, a current ratio of 1.60 and a debt-to-equity ratio of 0.72.

Bausch + Lomb (NYSE:BLCO) last released its quarterly earnings data on Wednesday, February 19th. The company reported $0.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.02. Bausch + Lomb had a positive return on equity of 3.35% and a negative net margin of 6.62%. The business had revenue of $1.28 billion during the quarter, compared to analysts’ expectations of $1.26 billion. During the same period in the prior year, the firm posted $0.24 EPS. The business’s quarterly revenue was up 9.1% compared to the same quarter last year. As a group, research analysts expect that Bausch + Lomb will post 0.74 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Blue Trust Inc. lifted its holdings in Bausch + Lomb by 68.3% in the 4th quarter. Blue Trust Inc. now owns 2,474 shares of the company’s stock valued at $48,000 after purchasing an additional 1,004 shares in the last quarter. State Street Corp raised its position in shares of Bausch + Lomb by 5.6% in the third quarter. State Street Corp now owns 28,450 shares of the company’s stock valued at $549,000 after buying an additional 1,510 shares during the last quarter. HighTower Advisors LLC lifted its stake in shares of Bausch + Lomb by 14.7% during the third quarter. HighTower Advisors LLC now owns 24,661 shares of the company’s stock valued at $476,000 after buying an additional 3,164 shares during the period. FNY Investment Advisers LLC acquired a new stake in Bausch + Lomb during the fourth quarter worth approximately $72,000. Finally, XTX Topco Ltd grew its stake in Bausch + Lomb by 25.4% in the 4th quarter. XTX Topco Ltd now owns 20,077 shares of the company’s stock worth $363,000 after acquiring an additional 4,065 shares during the period. 11.07% of the stock is currently owned by institutional investors and hedge funds.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.